Domain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2

Guillaume B E Stewart-Jones,Sayda M Elbashir,Kai Wu,Diana Lee,Isabella Renzi,Baoling Ying,Matthew Koch,Caralyn E Sein,Angela Choi,Bradley Whitener,Dario Garcia-Dominguez,Carole Henry,Angela Woods,LingZhi Ma,Daniela Montes Berrueta,Laura E Avena,Julian Quinones,Samantha Falcone,Chiaowen J Hsiao,Suzanne M Scheaffer,Larissa B Thackray,Phil White,Michael S Diamond,Darin K Edwards,Andrea Carfi,Guillaume B. E. Stewart-Jones,Sayda M. Elbashir,Caralyn E. Sein,Laura E. Avena,Chiaowen J. Hsiao,Suzanne M. Scheaffer,Larissa B. Thackray,Michael S. Diamond,Darin K. Edwards
DOI: https://doi.org/10.1126/scitranslmed.adf4100
IF: 17.1
2023-09-15
Science Translational Medicine
Abstract:With the success of messenger RNA (mRNA) vaccines against coronavirus disease 2019, strategies can now focus on improving vaccine potency, breadth, and stability. We designed and evaluated domain-based mRNA vaccines encoding the wild-type spike protein receptor binding domain (RBD) or N-terminal domain (NTD) alone or in combination. An NTD-RBD–linked candidate vaccine, mRNA-1283, showed improved antigen expression, antibody responses, and stability at refrigerated temperatures (2° to 8°C) compared with the clinically available mRNA-1273, which encodes the full-length spike protein. In BALB/c mice administered mRNA-1283 as a primary series, booster, or variant-specific booster, similar or greater immune responses from viral challenge were observed against wild-type, beta, delta, or omicron (BA.1) viruses compared with mRNA-1273–immunized mice, especially at lower vaccine dosages. K18-hACE2 mice immunized with mRNA-1283 or mRNA-1273 as a primary series demonstrated similar degrees of protection from challenge with SARS-CoV-2 Delta and Omicron variants at all vaccine dosages. These results support clinical assessment of mRNA-1283, which has now entered clinical trials (NCT05137236).
cell biology,medicine, research & experimental
What problem does this paper attempt to address?